Thomas Kuilman

Years Active: 2018-2023
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Sebastiaan M Schieven, Joleen J H Traets, Alex V Vliet, Martijn V Baalen, Ji-Ying Song, Marcos Da Silva Guimaraes, Thomas Kuilman, Daniel S Peeper
The Elongin BC complex negatively regulates AXL and marks a differentiated phenotype in melanoma. Molecular cancer research : MCR (2023)
Willemijn S M E Theelen, Thomas Kuilman, Katja Schulze, Wei Zou, Oscar Krijgsman, Dennis D G C Peters, Sten Cornelissen, Kim Monkhorst, Pranamee Sarma, Teiko Sumiyoshi, Lukas C Amler, Stefan M Willems, Johannes L G Blaauwgeers, Carel J M van Noesel, Daniel S Peeper, Michel M van den Heuvel, Marcin Kowanetz
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer. PloS one 14 (5) (2019)
Julia Boshuizen, Louise A Koopman, Oscar Krijgsman, Aida Shahrabi, Elke Gresnigt- van den Heuvel, Maarten A Ligtenberg, David W Vredevoogd, Kristel Kemper, Thomas Kuilman, Ji-Ying Song, Nora Pencheva, Jens Thing Mortensen, Marnix Geukes Foppen, Elisa A Rozeman, Christian U Blank, Maarten L Janmaat, David Satijn, Esther C W Breij, Daniel S Peeper, Paul W H I Parren
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature medicine 24 (2) (2018)
Thomas Kuilman, Daniel S Peeper
Phenotypic diversity drives paracrine drug tolerance. EMBO molecular medicine 9 (8) (2018)

Thomas Kuilman.css-eqlu8i{font-size:small;padding-left:4px;}